NEJM March 2026: Volume 394, Issue 10 – Latest Research

A recent study published today in the New England Journal of Medicine details the results of a Phase 3 clinical trial evaluating zorevunersen, an antisense oligonucleotide, for the treatment of Dravet syndrome in children and adolescents. The findings, appearing in the March 5, 2026 issue (Volume 394, Issue 10, pages 969-982), offer a potential new therapeutic avenue for this severe form of epilepsy. Dravet syndrome, a rare genetic disorder, typically begins in infancy and is characterized by frequent, prolonged seizures that are often resistant to traditional anti-epileptic medications.

Understanding Dravet Syndrome and the Role of SCN1A

Dravet syndrome is caused by mutations in the SCN1A gene, which provides instructions for making a protein channel crucial for regulating nerve cell excitability. These mutations typically lead to a loss of function of the SCN1A protein, disrupting the balance between excitation and inhibition in the brain. This imbalance is what drives the frequent seizures seen in individuals with Dravet syndrome. Currently, treatment focuses on managing symptoms with anti-epileptic drugs, but these often have limited effectiveness and significant side effects.

How Zorevunersen Works: Restoring Protein Balance

Zorevunersen is designed to address the underlying genetic cause of Dravet syndrome. It’s an antisense oligonucleotide, a type of drug that binds to messenger RNA (mRNA) – the molecule that carries genetic instructions from DNA to the protein-making machinery of the cell. Specifically, zorevunersen targets the mutated SCN1A mRNA, prompting the cell to degrade it. This, in theory, reduces the production of the faulty SCN1A protein and allows for increased production of the normal, functional protein. The goal is to restore a more balanced level of SCN1A protein activity in the brain.

The Phase 3 Trial: Design and Key Findings

The clinical trial, detailed in the New England Journal of Medicine, involved 148 participants aged 5 to 17 years with genetically confirmed Dravet syndrome. Participants were randomly assigned to receive either zorevunersen or a placebo (inactive substance) via lumbar puncture every four weeks for 48 weeks. The primary endpoint of the study was the change from baseline in the frequency of convulsive seizures.

The study demonstrated a statistically significant reduction in the frequency of convulsive seizures in the zorevunersen group compared to the placebo group. Specifically, the zorevunersen group experienced a 67.5% reduction in seizure frequency, compared to a 15.3% reduction in the placebo group. Secondary endpoints, including measures of overall seizure burden and quality of life, also showed improvements in the zorevunersen group. Though, it’s important to note that the study did not assess long-term outcomes or the potential for zorevunersen to completely eliminate seizures in all patients.

Safety Considerations and Observed Adverse Events

As with any medication, zorevunersen was associated with certain adverse events. The most common side effects reported in the trial included back pain, headache, and fever. These were generally mild to moderate in severity. More serious adverse events, such as temporary increases in liver enzymes, were observed in some participants, requiring monitoring and, in some cases, dose adjustments. The study authors emphasize the require for careful monitoring of patients receiving zorevunersen to manage potential side effects. Further information on the safety profile can be found on the NEJM website.

Limitations and Areas for Further Research

Although the results of this Phase 3 trial are promising, it’s crucial to acknowledge the study’s limitations. The trial population was relatively small, and the duration of follow-up was limited to 48 weeks. Longer-term studies are needed to assess the sustained efficacy and safety of zorevunersen. The study focused on a specific age range (5-17 years), and further research is needed to determine whether zorevunersen is effective and safe in younger children or adults with Dravet syndrome. The study also did not include a diverse representation of patients, which could limit the generalizability of the findings.

What This Means for Patients and Families

The findings from this trial represent a significant step forward in the treatment of Dravet syndrome. For families living with this challenging condition, zorevunersen offers a potential new hope for reducing seizure frequency and improving quality of life. However, it’s important to remember that zorevunersen is not a cure, and it may not be effective for all patients.

Currently, zorevunersen is under review by regulatory agencies, including the Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMA). If approved, it would be the first disease-modifying therapy available for Dravet syndrome, addressing the underlying genetic cause of the disorder. The New England Journal of Medicine regularly publishes updates on emerging therapies and clinical trials.

The Path Forward: Regulatory Review and Potential Access

Following the publication of these results, the next step is the completion of the regulatory review process. The FDA and EMA will carefully evaluate the data from the Phase 3 trial, as well as other relevant information, to determine whether to approve zorevunersen for clinical use. If approved, access to the medication will likely be determined by healthcare providers on a case-by-case basis, taking into account the individual patient’s needs and medical history.

Ongoing research will continue to explore the potential of zorevunersen, including studies to optimize dosing regimens, identify biomarkers that predict treatment response, and evaluate its effectiveness in combination with other anti-epileptic medications. An image challenge related to a patient presenting with fever, muscle aches, and vomiting was also published on March 5, 2026, by the New England Journal of Medicine (Image Challenge), highlighting the complexities of differential diagnosis in patients with neurological symptoms.